Close



Feb 2, 2023 04:31PM
Feb 2, 2023 04:30PM
Feb 2, 2023 04:30PM
Jan 31, 2023 08:27AM
Jan 31, 2023 08:24AM
Jan 31, 2023 08:24AM
Jan 10, 2022 07:27AM Amarin Corp. (AMRN) Prelim. Q4 Revenue Misses Consensus
Jan 10, 2022 07:00AM
Jan 10, 2022 07:00AM
May 22, 2020 09:29AM
Feb 25, 2020 04:05PM
Feb 25, 2020 04:05PM
Feb 6, 2020 09:26PM
Feb 6, 2020 09:26PM Amarin Honored by BioNJ with Innovator Award for VASCEPA® Development and Regulatory Approval
Dec 16, 2019 09:01AM
Dec 2, 2019 09:45AM
Dec 2, 2019 06:04AM
Dec 2, 2019 06:00AM
Dec 2, 2019 06:00AM
Nov 22, 2019 01:26PM
Nov 20, 2019 11:11AM Amarin (AMRN) Smacked on Bearish Call, But Gilead (GILD) Adding Vascepa to its NASH Combo Raises Eyebrows
Nov 18, 2019 05:31PM
Nov 18, 2019 05:30PM
Nov 18, 2019 05:30PM
Nov 18, 2019 12:15PM
Nov 18, 2019 12:15PM
Nov 15, 2019 09:23AM
Nov 15, 2019 07:24AM H.C. Wainwright Reiterates Buy Rating, $51 PT on Amarin (AMRN) Following FDA AdCom
Nov 14, 2019 05:49PM
Nov 14, 2019 05:35PM
Nov 14, 2019 05:34PM
Nov 14, 2019 05:34PM
Nov 14, 2019 10:38AM
Nov 14, 2019 09:10AM
Nov 14, 2019 06:59AM Amarin Corp. (AMRN) Stock Trading Halted Today for Scheduled FDA Advisory Committee Review of sNDA Seeking New Indication for Vascepa
Nov 14, 2019 06:59AM
Nov 14, 2019 06:59AM
Nov 13, 2019 08:27AM
Nov 12, 2019 10:18AM
Nov 12, 2019 09:35AM
Nov 12, 2019 09:25AM
Nov 11, 2019 01:19PM New Analysis Shows Icosapent Ethyl (Vascepa®) Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthcare Costs When Used to Treat High-Risk Patients with Cardiovascular Disease
Nov 11, 2019 01:19PM
Nov 11, 2019 10:56AM
Nov 11, 2019 06:35AM
Nov 11, 2019 06:30AM
Nov 11, 2019 06:30AM
Nov 6, 2019 06:13AM
Nov 5, 2019 11:03AM Amarin Corp. (AMRN) November IV bid into EPS and outlook
Nov 5, 2019 05:00AM

12,612 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All